Nyxoah SA (EBR:NYXH)
Belgium · Delayed Price · Currency is EUR 1.310
-0.038 (-2.82%)
At close: Sep 18, 2026
Nyxoah Company Description
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea.
Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea.
The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 154 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 045 90 75 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | Euronext Brussels |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert Taub MBA | Co-Founder and Chairman |
| Bruno Onkelinx | Chief Technical Officer |
| John Landry | Chief Financial Officer |
| Jeyakumar Subbaroyan | Chief Science Officer |
| Pearson Dennis | Investor Relations Associate |
| An Moonen | General Counsel |
| Geeta Kaveti | Chief Compliance Officer |
| Loic Moreau | President of International |
| Dr. Maurits S. Boon | Chief Medical Officer |
| Scott Holstine | Chief Commercial Officer |